BMY
Bristol-Myers Squibb Company
October 5, 2026 · pre-market
- Rarity
- 1.30
- Peak move
- −4.56%
- Float cap
- $124.2B
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines for serious diseases. Its therapies target oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. Products are sold worldwide, primarily to wholesalers, distributors, specialty pharmacies, and, to a lesser extent, retailers, hospitals, clinics, government agencies, and patients.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
9 events · 0 from SEC or newswire · 0 timed with the move- Key event
analyst_ratingLeerink Partners analyst David Risinger downgraded Bristol Myers Squibb to Market Perform from Outperform and cut the price target to $59 from $73, citing doubt over Phase 3 readouts for admilparant, milvexian and Cobenfy.
- Key event
peer_disclosureImmunome amended its license agreement with Bristol-Myers Squibb on October 2, 2026, paying $20 million cash and issuing 4,425,487 shares to remove all milestone and royalty obligations and be assigned patent rights for varegacestat (AL102) and AL101.
filing_delayZacks Research raised its Q3 2028 earnings estimate for Bristol Myers Squibb to $1.17 per share from $1.16 and maintained a Strong Buy rating.
- Key event
dividend_changeBristol Myers Squibb's $0.63 quarterly dividend, declared September 16, 2026, has an ex-dividend date of October 2, 2026, payable November 2 to stockholders of record.
reg_fd_disclosureBristol Myers Squibb amended the protocol for its Phase 3 ALOFT program of admilparant for pulmonary fibrosis, disclosing a limited number of liver injury events including one patient death from multi-organ failure after acute hepatic injury.
regulatory_approvalThe FDA approved an expanded indication for Bristol Myers Squibb's CAMZYOS (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients weighing at least 30 kg, based on the Phase 3 SCOUT-HCM trial of 44 adolescents.
policy_changeA finalized Trump administration rule to cut hospital drug prices for Medicare patients (the GLOBE model) may apply to as few as four drugmakers after exempting companies with separate most-favored-nation pricing deals, with HHS cutting projected Part B savings to about $440 million from $11.9 billion.
reg_fd_disclosureBristol Myers Squibb announced the second year of its Champions in Care campaign, including a $1 million grant program for nonprofit organizations serving medically underserved US communities, with nominations open until November 30, 2026.
analyst_ratingBMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb with an unchanged $60 price target, citing pipeline risk balanced against immuno-oncology and hematology cash flows.